Published January 27, 2026
OA background
Back in medical school I learned a simple but disappointing story. Osteoarthritis (OA) is wear and tear breakdown of the joints and we don’t have any effective treatment for the cartilage itself. So we would manage the pain, replace the joint and that’s it. Glucosamine was tried but it didn’t modify the disease as hoped. So we thought essentially “over-use your joints enough and eventually they wear out.” Sort of like tires on a car. Mileage equals inevitable degradation of the treads.
But that story has some holes if you think about it. If arthritis was purely mechanical, we’d expect it to behave predictably. Heavy laborers would all develop severe arthritis and marathon runners would be crippled by 50. Sedentary people would be spared. Everyone would eventually get it if they lived long enough. However, that’s not what we see.
Some people reach their 70s with pristine joints while others develop debilitating hip or knee arthritis in their 40s. One knee deteriorates while the other stays relatively normal. And how about dogs? When they get to about twelve (only) they develop osteoarthritis, regardless of how much they’ve “used” their joints. So this raises a question: is osteoarthritis really just wear and tear, or is something more subtle going on?
The Real Problem With Cartilage
Cartilage gets described as padding – inert cushioning between bones. But that’s misleading. Cartilage is living tissue. It responds to stress, inflammation, metabolic signals, and the big one – aging at the cellular level.
Current evidence suggests osteoarthritis arises from multiple factors converging: chronic low-grade inflammation, altered metabolism in cartilage cells, loss of regenerative signaling, impaired response to mechanical stress, and aging-related molecular shifts.
In other words, cartilage doesn’t just wear out. It loses its ability to repair and maintain itself. That distinction matters. Because if osteoarthritis is a failure of regeneration rather than inevitable destruction, maybe there is a target for treatment.
In fact, A study published recently in Science suggests we may need to rethink things.
A Molecule That Changes the Conversation
This study hit the newswires a few days ago and caught my attention. It’s not a promise for a cure. But it challenged a long-held assumption.
Researchers studied a small molecule that inhibits an enzyme called 15-PGDH. They injected it directly into arthritic joints of mice.
Why is that interesting? 15-PGDH breaks down prostaglandin E2 (PGE2), a signaling molecule involved in tissue repair. By blocking this enzyme, local PGE2 levels rise (right there in the joint fluid). This rise of PGE2 caused something amazing. Cartilage started regenerating! Not just slowing degeneration. Not masking pain. An actual increase in cartilage thickness and joint integrity!!
In mice with moderate osteoarthritis – whether from aging or injury – cartilage thickness increased, joint structure improved, and repair pathways reactivated. Even after arthritis was already part way along.
This matters because cartilage regeneration has long been considered nearly impossible. As mentioned, osteoarthritis has been treated as progressive and irreversible. This study suggests that we may have found a way forward.
Is This Ready for Humans?
Unfortunately not quite yet. (If there are any mice reading though, you guys are all set). This was animal research – and as is often the case – a really cool treatment in mice does not always translate to humans. Human joints are more complex than mouse joints… However, sometimes the treatment does translate. That’s why we do these experiments. Could it work in humans?
A Phase 1 Trial underway
Already this PGE2 pathway is under HUMAN investigation. The same pathway is being inhibited with an oral version of the inhibitor of 15-PGDH. It’s being tried out to see if it can help with sarcopenia (age-related muscle loss). Phase 1 focuses on safety, and early data suggest acceptable tolerability. Phase 2 trials may begin as early as mid-2026.
That tells us this pathway is already considered clinically relevant, and translation to human use is being actively explored. I really hope this works out.
What This Means Right Now
Even before any new therapy becomes available, this research shifts how we should think about osteoarthritis.
If cartilage regeneration may be biologically possible under the right conditions, then preserving cartilage today becomes more important than we realized.
That means avoiding unnecessary joint damage, reducing chronic inflammation, maintaining muscle strength and joint stability, and preserving range of motion and healthy loading patterns. In other words I think we should all work at keeping “some cartilage around.” If we have some left, maybe a joint injection in the future can cause it to regenerate.
Osteoarthritis as an Aging Disease
This discovery also reframes osteoarthritis alongside other aging-related conditions like sarcopenia, bone density loss, skin thinning, and cognitive decline.
Osteoarthritis may reflect declining regenerative signaling rather than unavoidable wear and tear. This opens the door to other disease-modifying approaches, regenerative biology, and combination strategies that address both mechanics and molecular aging.
Where Do We Go From Here?
Will this molecule become a treatment? Will human cartilage respond the same way? Will long-term safety hold up?
Time will tell.
Biology is complex. But this is the kind of research that moves medicine forward – not flashy headlines, but careful, scientific work that challenges old assumptions. For the first time in a long while, osteoarthritis research is talking about repair, not just replacement.
It’s early days with this pathway – but it is hopeful when you see the same pathway affecting multiple aging-related conditions – osteoarthritis, muscle loss, etc- it suggests we may be looking at something fundamental about how our bodies lose the ability to repair themselves as we age.
Blessings,
Dr. Jeff Ponke,
( bonus material )
Also recently published…this same 15-PGDH pathway that affects cartilage and muscle also appears to play a role in liver health. This study showed that inhibiting 15-PGDH dramatically improved fatty liver disease in mice – the kind that comes from metabolic dysfunction. This is the same type of fatty liver that affects more than 30 percent of the global population. These mice had a significant drop in liver fibrosis scores and cell death rates plummeted. Also the mice lost body fat while gaining lean mass. Their insulin resistance improved too. (throw in a free set of Ginsu knives and I am sold!) References: Singla M, et al. Inhibition of 15-hydroxy prostaglandin dehydrogenase promotes cartilage regeneration. Science, November 2025. Udoh US, et al. Inhibition of the prostaglandin-degrading enzyme 15-PGDH ameliorates MASH-associated apoptosis and fibrosis in mice. Cells, June 2025.
References:
Singla M, et al. Inhibition of 15-hydroxy prostaglandin dehydrogenase promotes cartilage regeneration. Science, November 2025.
Udoh US, et al. Inhibition of the prostaglandin-degrading enzyme 15-PGDH ameliorates MASH-associated apoptosis and fibrosis in mice. Cells, June 2025.
Leave a comment